invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...

invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor...